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ABSTRACT
We examined our hypothesis that heme-oxygenase-1 (HO-1)-
derived carbon monoxide (CO) inhibits the release of high-
mobility group box 1 (HMGB1) in RAW264.7 cells activated with
lipopolysaccharide (LPS) in vitro and in LPS- or cecal ligation
and puncture (CLP)-induced septic mice in vivo, so that HO-1
induction or CO improves survival of sepsis in rodents. We
found that pretreatment with HO-1 inducers (hemin, cobalt
protoporphyrin IX) or transfection of HO-1 significantly inhibited
HMGB1 release, which was blocked by HO-1 small interfering
RNA, in cells activated by LPS. Carbon monoxide-releasing
molecule 2 (CORM-2) but not bilirubin or deferoxamine inhib-
ited HMGB1 release in LPS-activated macrophages. Oxyhemo-
globin reversed the effect of HO-1 inducers on HMGB1 release.
Translocation of HMGB1 from nucleus to cytosol was signifi-
cantly inhibited by HO-1 inducers, CORM-2, or HO-1 transfec-
tion. Neutralizing antibodies to tumor necrosis factor (TNF)-,
interleukin (IL)-1, interferon-, and N-nitro-L-arginine methyl
ester hydrochloride but not N-[2-(cyclohexyloxyl)-4-nitrophe-
nyl]-methane sulfonamide (NS-398) significantly inhibited
HMGB1 release in LPS-activated cells. Production of TNF-,
IL-1, and IFN- was significantly reduced by pretreatment of
HO-1 inducers, CORM-2, or HO-1 transfection in LPS-acti-
vated cells. Plasma levels of HMGB1 in mice challenged with
LPS or CLP were significantly reduced by the administration of
HO-1 inducers or CORM-2, which was accompanied by either
reduction (pretreatment) or no change (delayed administration)
of serum TNF- and IL-1 levels. Regardless of pretreatment or
delayed administration, CORM-2 and hemin rescued mice from
lethal endotoxemia and sepsis induced by LPS or CLP. Taken
together, we concluded that HO-1-derived CO reduces
HMGB1 release in LPS-activated cells and LPS- or CLP-in-
duced animal model of sepsis.
Sepsis is defined as a systemic inflammatory response
syndrome from a microbial infection that results from exces-
sive stimulation of the host immune system by pathogen
components to produce various proinflammatory cytokines,
and their overproduction causes systemic inflammation that
can lead to the lethal multiple organ damage (Oberholzer et
al., 2001). High-mobility group box 1 (HMGB1) is a chroma-
tin-binding protein that participates in maintaining nucleo-
some structure and regulation of gene transcription (Lands-
man and Bustin, 1993). Various evidence indicated that
HMGB1 is a necessary and sufficient late mediator of severe
sepsis (Wang et al., 1999; Yang et al., 2004). Once released,
HMGB1 can bind to cell-surface receptors, such as the recep-
tor for advanced glycation end products and Toll-like recep-
tors 2 and 4, and mediate various cellular responses, chemo-
tactic cell movement, and release of proinflammatory
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cytokines (Andersson et al., 2000; Park et al., 2004; Rouhi-
ainen et al., 2007). The administration of anti-HMGB1 anti-
bodies or inhibitors (e.g., ethyl pyruvate, nicotine) signifi-
cantly protected mice from lethal sepsis (Wang et al., 1999,
2004a; Ulloa et al., 2002; Yang et al., 2004). Thus, inhibition
of HMGB1 release is a prospective target for therapeutic
intervention against sepsis.
Heme oxygenase-1 (HO-1), a stress-responsive protein that
can be induced by stimulants such as inflammatory cyto-
kines, heat shock, heavy metals, and oxidants, degrades
heme into three products: Fe2, biliverdin, and carbon mon-
oxide (CO). Biliverdin is subsequently converted into biliru-
bin by biliverdin reductase. The increased level of Fe2 stim-
ulates the synthesis of ferritin (iron-bound compound), which
is known as a cytoprotective, antioxidant protein. HO-1 sys-
tem exerts antiapoptotic, antioxidant, and immunomodula-
tory functions in various situations (Ryter et al., 2006). It has
already been reported that HO-1 induction improves animal
survival in lethal endotoxemia (Otterbein et al., 1995; Yu and
Yao, 2008). We hypothesized that HO-1-derived CO may
inhibit HMGB1, a necessary and sufficient late mediator of
severe sepsis, so that HO-1 induction improves animal sur-
vival in lethal sepsis. Thus, the aim of the present study was
to investigate the following questions: 1) how HO-1 inducers
or HO-1 gene transfection inhibit the expression and release
of HMGB1 in murine RAW264.7 macrophages when acti-
vated with LPS; 2) whether CO is responsible for the inhibi-
tion of expression and release of HMGB1 by HO-1 induction;
and 3) whether CO improves survival in LPS- or CLP-treated
mice. To do this, we used pharmacological agents such as
Fig. 1. Hemin, CoPPIX, and mHO-1 attenuated
the endotoxin-induced HMGB1 release in RAW
264.7 cells. A, cells were stimulated with LPS (1
g/ml) for 4, 8, 16, and 24 h, and culture medium
samples were concentrated for HMGB1 detec-
tion as described under Materials and Methods.
B, cells were treated with hemin or CoPPIX at 1,
5, 10, and 25 M for 16 h, and then HO-1 protein
levels were determined by Western blot. C, LPS
(1 g/ml) stimulated macrophages in the pres-
ence or absence of hemin or CoPPIX in various
doses for 16 h, HMGB1 release was identified,
and the main Ponceau band was used as a load-
ing control. D, cells were transfected with si-
HO-1 or scramble as described under Materials
and Methods. After transfection, cells were pre-
treated with hemin (10 M) or CoPPIX (10 M)
for 1 h and stimulated with LPS (1 g/ml);
HMGB1 and HO-1 levels were determined. E,
cells were transfected with mHO-1 or empty vec-
tor as described under Materials and Methods
and then stimulated with LPS. After 16 h, cul-
ture medium was subjected to HMGB1 levels
determination, and cells were subjected to whole
lysis for HO-1 detection by Western blot. Data
are presented as mean  S.D. of three indepen-
dent experiments. One-way analysis of variance
was used to compare multiple group means fol-
lowed by Newman-Keuls test (significance com-
pared with control, , P  0.05; significance com-
pared with LPS, †, P  0.05).
174 Tsoyi et al.
hemin and cobalt protoporphyrin IX (CoPPIX) as HO-1 in-
ducers and tricarbonyldichlororuthenium (II) dimer
([Ru(CO)3Cl2]2, CORM-2) as a CO-releasing molecule. Very
recently, Takamiya et al. (2008) reported that elevated cir-
culating levels of HMGB1 contributed to LPS-induced mor-
tality in the absence of HO-1 rodents, which further rein-
forces our hypothesis.
Materials and Methods
Materials. Anti-HMGB1 was purchased from Abcam (Cambridge,
MA), anti-iNOS from Transduction Laboratories (Lexington, KY),
anti--actin and anti-heme oxygenase-1 from Santa Cruz Biotech-
nology (Santa Cruz, CA). Neutralizing antibodies to TNF-, IL-1,
and INF- were provided by R&D Systems (Minneapolis, MN). En-
hanced chemiluminescence Western blotting detection reagent was
from GE Healthcare (Chalfont St. Giles, Buckinghamshire, UK). All
other chemicals, including lipopolysaccharide (LPS, Escherichia coli
0111:B4), cobalt protoporphyrin IX, hemin, CORM-2, NS-398, and
N-nitro-L-arginine methyl ester hydrochloride (L-NAME) were pur-
chased from Sigma-Aldrich (St. Louis, MO).
Cell Culture. RAW 264.7 cells were obtained from the American
Type Culture Collection (Manassas, VA). The cells were grown in
RPMI 1640 medium supplemented with 25 mM HEPES, 100 U/ml
penicillin, 100 g/ml streptomycin, and 10% heat-inactivated fetal
calf serum.
Cell Stimulation. RAW 264.7 cells were plated at a density of 1 
107 cells per 100-mm dish. The cells were rinsed with fresh medium
and stimulated with LPS (1 g/ml) in the presence of different
Fig. 2. Effect of CORM-2, bilirubin, and DFO on endotoxin-induced
HMGB1 release in RAW264.7 cells. Cells were pretreated with CORM-2
(A) or bilirubin (B) for 1 h and then stimulated with LPS (1 g/ml) for
16 h. RuCl3 was used as a negative control for CORM-2. C, DFO (500
g/ml) was administrated for 1 h, and later hemin (10 g/ml) or CoPPIX
(10 g/ml) was administrated. After 1 h, cells were stimulated with LPS
(1 g/ml) for 16 h. HMGB1 levels in culture medium were determined by
Western blot. Data are presented as mean  S.D. of three independent
experiments. One-way analysis of variance was used to compare multiple
group means followed by Newman-Keuls test (significance compared with
control, , P  0.05; significance compared with LPS, †, P  0.05).
Fig. 3. Inhibitory effect of HO-1 on LPS-induced HMGB1 release in
RAW264.7 cells is dependent on CO. Cells were treated with HbO2 (20
g/ml), and then hemin (10 g/ml) or CoPPIX (10 g/ml) was adminis-
trated. After that, cells were stimulated with LPS (1 g/ml). Culture
medium was collected and subjected to HMGB1 analysis by Western blot.
Data are presented as the mean  S.D. of three independent experi-
ments. One-way analysis of variance was used to compare multiple group
means followed by Newman-Keuls test (significance compared with con-
trol, , P  0.05; significance compared with LPS, †, P  0.05).
Fig. 4. Hemin, CoPPIX, and CORM-2 impair cytoplasmic translocation of
HMGB1 in activated macrophages. Cells were pretreated with hemin (10
M), CoPPIX (10 M), or CORM-2 (100 M) for 1 h and then stimulated
with LPS (1 g/ml) for 16 h. After treatment, cells were subjected to
nuclear/cytosol fractionation and immunoblotted against HMGB1 anti-
body as described under Materials and Methods. The data are from two
independent experiments.
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concentration of pharmacological agents. At 16 h after stimulation,
levels of HMGB1 or iNOS were determined. Oxyhemoglobin (HbO2)
was prepared by the reduction of bovine hemoglobin with sodium
hydrosulfite followed by gel filtration with a prepacked disposable
column (PD-10; Pfizer, New York, NY), previously equilibrated with
50 mM Tris/HCl at pH 7.4 (Salvemini et al., 1989). The concentration
of HbO2 was determined using a spectrophotometer (Lambda 5;
PerkinElmer Life and Analytical Sciences, Waltham, MA) at 576 nm
wavelength, according to Kondo et al. (1989).
NO Assay. Nitric oxide was measured as its stable oxidative
metabolite, nitrite, as described by Kang et al. (1999). At the end of
incubation, 100 l of the culture medium was mixed with the same
volume of Griess solution (0.1% naphthylethylenediamine and 1%
sulfanilamide in 5% phosphoric acid). Light absorbance was mea-
sured at 550 nm, and the nitrite concentration was determined using
a curve calibrated on sodium nitrite standards.
ELISA. The levels of TNF-, INF-, and IL- in the culture
medium were determined using commercially available ELISA kits
from R&D Systems according to the provided manuals.
HMGB1 Analysis. Culture medium samples were briefly centri-
fuged. The same volumes of samples were then concentrated 40-fold
with Amicon Ultra-4–10000 NMWL (Millipore, Billerica, MA). Cen-
trifugation conditions were fixed-angle (35°) and 7500g for 20 min at
4°C. Blood was collected by cardiac puncture into a sodium heparin-
containing tube. After centrifugation, plasma samples were filtered
and concentrated through Centricon YM-100 and YM-10 (Millipore),
respectively. The concentrated samples were subjected to SDS-poly-
acrylamide gel electrophoresis electrophoresis. Ponceau staining was
used as loading control.
Western Blot. The cytoplasmic/nuclear fractionation was per-
formed using nuclear/cytosol fractionation kit (BioVision, Mountain
View, CA) according to the manufacturer’s manual. Whole-cell ly-
sates were performed using buffer containing 0.5% SDS, 1% Nonidet
P-40, 1% sodium deoxycholate, 150 mM NaCl, 50 mM Tris-Cl, pH
7.5, and protease inhibitors. Concentrated supernatants, to detect
HMGB1, and whole-cell lysates, to detect iNOS, -actin, and HO-1 as
well as nuclear, cytosol lysates were subjected to electrophoresis in
different-percentage polyacrylamide gels depending on the size of
interested protein. The gels were transferred to polyvinylidene di-
fluoride membranes by semidry electrophoretic transfer at 15 V for
60 to 75 min. The membranes was stained with Ponceau S solution
(2 g/ml) for 5 min to determine the efficiency of transfer or/and
protein loading levels per track. Then the polyvinylidene difluoride
membranes were blocked overnight at 4°C in 5% bovine serum
albumin. The cells were incubated with primary antibodies diluted
1:500 in Tris-buffered saline/Tween 20 containing 5% bovine serum
albumin for overnight in 4°C and then incubated with secondary
antibody at room temperature for 1 h. The signals were detected by
enhanced chemiluminescence.
Transfection of HO-1 Gene into RAW264.7 Cells. For HO-1
transfection, cells were washed twice with serum-free media and
Fig. 5. Effect of TNF-, IL-1, and INF- neutralization and NO (iNOS)
and COX-2 inhibition on the endotoxin-induced HMGB1 release in mac-
rophages. Cells were pretreated with neutralizing antibody (Nab) TNF-
(100 g/ml), Nab IL-1 (100 g/ml), Nab INF- (500 g/ml), L-NAME (300
M), or NS-398 (50 M) for 1 h and treated with LPS (1 g/ml) for 16 h.
After incubation, culture medium samples were subjected to HMGB1
levels determination as described under Materials and Methods. Data are
presented as the mean  S.D. of three independent experiments. One-
way analysis of variance was used to compare multiple group means
followed by Newman-Keuls test (significance compared with control, ,
P  0.05; significance compared with LPS, †, P  0.05).
Fig. 6. Effect of HO-1 up-regulation and CORM-2 on
the release of various cytokines and NO (iNOS) in
LPS-activated macrophages. A to D, cells were in-
cubated with hemin (10 M), CoPPIX (10 M), and
CORM-2 (100 M) for 1 h or were transfected with
mHO-1 and later activated with LPS for 16 h. After
incubation time, culture medium samples were sub-
jected to TNF- (A), INF- (B), and IL-1 (C) deter-
mination by the appropriate ELISA kit, and NO
production (D) was measured by NO assay as de-
scribed under Materials and Methods. Cells were
harvested by total lysis, and iNOS protein (D) levels
were determined by Western blot. Data are pre-
sented as the mean  S.D. of three independent
experiments. One-way analysis of variance was
used to compare multiple group means followed by
Newman-Keuls test (significance compared with
control, , P  0.01; significance compared with
LPS, †, P  0.05 or ††, P  0.01).
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incubated with HO-1 cDNA (from Dr. Augustine M. K. Choi; Uni-
versity of Pittsburgh, Pittsburgh, PA) that had been subcloned into
the mammalian pcDNA 3 expression vector and Superfect transfec-
tion reagent (QIAGEN, Valencia, CA). After 4 h of incubation, the
media were removed, and the cells were incubated in appropriate
media for 16 h.
siRNA Technique. HO-1 small interfering RNA (siRNA) and
scramble siRNA were purchased from Invitrogen (Carlsbad, CA).
The sequence of mouse HO-1 siRNA (5-end to 3-end) is UUACAUG-
GCAUAAAUUCCCACUGCC. The siRNA was transfected into
RAW264.7 cells according to the manufacturer’s protocol using
transfection reagent SuperFect from QIAGEN. The cells were incu-
bated with 100 nM HO-1 or scramble siRNA for 48 h in serum- and
antibiotic-free media. Then the cells were incubated for 12 h in media
containing antibiotics and fetal bovine serum, and cells were washed
and pretreated with or without Hemin or CoPPIX after LPS stimu-
lation.
Animal Model of Endotoxemia and Sepsis. Endotoxemia was
induced in BALB/c mice (male aged 7–8 weeks, 20–25 g) by intra-
peritoneal injection of bacterial endotoxin (LPS 15 mg/kg). To induce
sepsis, BALB/c mice were anesthetized with ketamine (30 mg/kg)
and xylazine (6 mg/kg). Next, a 2-cm midline incision was performed
to allow exposure of the cecum with adjoining intestine. The cecum
was tightly ligated with a 3.0-silk suture at 5.0 mm from the cecal tip
and punctured once with a 22-gauge needle. The cecum was then
gently squeezed to extrude a small amount of feces from the perfo-
ration sites and returned to the peritoneal cavity. The laparotomy
site was then stitched with 4.0 silk. In sham control animals, the
cecum was exposed but not ligated or punctured and then returned
to the abdominal cavity. Mice were maintained in accordance with
the Guide for the Care and Use of Laboratory Animals (Institute of
Laboratory Animal Resources, 1996) and were treated ethically. The
protocol was approved in advance by the Animal Research Commit-
tee of the Gyeongsang National University.
Statistical Evaluation. Data are expressed as the mean  S.D.
of results obtained from the number of replicate treatments. Differ-
ences between data sets were assessed by one-way analysis of vari-
ance followed by Newman-Keuls tests. P  0.05 or P  0.01 was
accepted as statistically significant.
Results
Up-Regulation of HO-1 Attenuates Endotoxin-In-
duced Release of HMGB1. HO-1 is known as a potent
regulator of inflammatory cytokines, but its effect on
HMGB1 in macrophages was not yet determined. Figure 1A
shows that HMGB1 release becomes detectable at 16 h after
LPS administration in RAW264.7 cells, confirming that
HMGB1 is the late proinflammatory mediator (Wang et al.,
1999). To determine whether HO-1 protein overexpression
can down-regulate HMGB1 release, we pretreated macro-
phages with CoPPIX or hemin (potent HO-1 inducers, Fig.
1B) for 1 h and then stimulated with LPS for 16 h. HMGB1
extracellular expression was significantly induced by LPS,
but HO-1 inducers could overwhelm this induction in a dose-
dependent manner (Fig. 1C). Next, we asked whether the
inhibitory effect of hemin and CoPPIX is mediated by HO-1
induction or not. As shown in Fig. 1D, HO-1 inducers failed to
inhibit HMGB1 levels in the presence of si-HO-1 RNA. Fi-
nally, in mHO-1-transfected cells, HMGB1 release was in-
hibited in RAW264.7 cells activated with LPS (Fig. 1E).
These results suggest that up-regulation of HO-1 can de-
crease HMGB1 extracellular level in macrophages stimu-
lated with LPS.
Effect of HO-1 Metabolites on HMGB1 Release by
LPS. Protective effect of HO-1 has been associated with its
main metabolites such as Fe2, bilirubin, and CO (Ryter et
al., 2006). Thus, to clarify the role of each product of HO-1, we
used bilirubin, CORM-2, CO-releasing molecule, and defer-
oxamine mesylate (iron chelator, DFO). Our results showed
that only CO can modulate LPS-induced HMGB1 release
(Fig. 2A), suggesting that the inhibitory effect HO-1 on
HMGB1 release may be due to CO release. Bilirubin (Fig. 2B)
or Fe2 (Fig. 2C) did not show its involvement in the HO-1-
mediated inhibitory effect. To confirm that CO derived from
HO-1 induction decreases HMGB1 release in cells activated
with endotoxin, we analyzed HMGB1 release by Western blot
from the media in the presence of oxyhemoglobin (HbO2, CO
chelator). As shown in Fig. 3, inhibitory effect of hemin and
CoPPIX was reversed by HbO2.
CoPPIX, Hemin, and CORM-2 Inhibit the Transloca-
tion of HMGB1 from the Nucleus to the Cytoplasm.
Consistent with previous reports, quiescent macrophages
constitutively express HMGB1 and maintain it in the nu-
cleus. However, activation of monocytes and macrophages by
LPS results in the translocation of HMGB1 from the nucleus
into the cytosol (Gardella et al., 2002). Keeping in mind that
hemin, CoPPIX, and CORM-2 down-regulated HMGB1 re-
Fig. 7. Hemin and CORM-2 administration protect mice from lethal
endotoxemia and sepsis. A and B, BALB/c mice were pretreated for 2 h
with hemin (10 mg/kg i.p., n  20), hemin  ZnPPIX (10 and 5 mg/kg i.p.,
respectively, n  20) CORM-2 (30 mg/kg i.p., n  20), ruthenium chloride
(30 mg/kg i.p., n  20), or DMSO (i.p., n  20) for 2 h. Then mice were
subjected to lethal endotoxemia (LPS, 15 mg/kg i.p.) (A) or sepsis (induced
by CLP) (B). At 12, 24, 48, 72, and 96 h after the onset of
endotoxemia or sepsis, animals were intraperitoneally administered with
DMSO, hemin (10 mg/kg), or CORM-2 (30 mg/kg). Survival was moni-
tored daily for up to 2 weeks. The results are the mean  S.D. of three
independent experiments. , P  0.01 compared with DMSO-treated
animals.
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lease into extracellular milieu, we were interested in whether
these agents can affect relocalization of HMGB1 in LPS-
stimulated RAW 264.7 cells. Cells were incubated for 16 h
with LPS in the absence or presence of hemin, CoPPIX, or
CORM-2. After incubation, cells were subjected to nuclear/
cytosol fractionation. All three pharmacological agents sig-
nificantly prevented HMGB1 translocation from nucleus into
cytoplasm (Fig. 4), thereby inhibiting HMGB1 release.
Effect of Early-Phase Cytokines, iNOS, and COX-2 on
the Endotoxin-Induced HMGB1 Release. LPS is a spe-
cific ligand for Toll-like receptor 4, which can activate the
induction of proinflammatory cytokines (TNF-, IL-1) and
INF- through MyD88-dependent and -independent path-
ways, respectively (Sato et al., 2002). iNOS and COX-2 are
inducible isoforms of nitric-oxide synthase and cyclooxygen-
ase, respectively. They were both documented as potent
proinflammatory genes. In this experiment, we tested
whether early-phase cytokines and/or iNOS and COX-2 are
linked with HMGB1 release in LPS-stimulated macrophages.
As shown in Fig. 5, neutralizing antibodies to TNF-, IL-1,
and INF- significantly prevented HMGB1 release by LPS.
In addition, treatment with L-NAME (iNOS inhibitor) but not
NS-398 (COX-2 inhibitor) showed a reduction in HMGB1
level in cell culture medium after LPS stimulation in
RAW264.7 cells. These data propose that TNF-, IL-1,
INF-, and iNOS are involved in HMGB1 release but not
COX-2 (Fig. 5).
Effect of HO-1/CO Up-Regulation on the Expression
of TNF-, IL-1, INF-, and iNOS (NO) in LPS-Stimu-
lated Macrophages. In a previous experiment, we deter-
mined that HMGB1 is dependent on TNF-, IL-1, INF-,
and NO (iNOS) production. It was interesting for us to know
whether HO-1 up-regulation or CO can affect the production
of these molecules. LPS greatly induced the production of
cytokines and NO by the induction of iNOS in murine mac-
rophages. However, these effects were abrogated in the pres-
ence of CoPPIX, hemin, mHO-1, and CORM-2 (Fig. 6, A–D),
suggesting that the inhibitory effect of HO-1 up-regulation
and CO-releasing molecule on HMGB1 release can be due to
the inhibition of production of early-phase cytokines and
iNOS (NO) induction in macrophages.
Hemin and CORM-2 Reduced HMGB1 Release and
Protected Against Lethal Endotoxemia and Sepsis. In
light of the capacity of CoPPIX, hemin, and CORM-2 in
attenuating LPS-induced HMGB1 release, we explored their
efficacy in the animal model of lethal endotoxemia and sep-
sis. Administration of hemin and CORM-2 significantly at-
tenuated animal death during lethal endotoxemia (Fig. 7A).
Although endotoxemia is useful to investigate the complex
cytokine cascades of sepsis, a more clinically relevant animal
model is CLP. We asked whether HO-1 inducer or CORM-2
can attenuate animal death stimulated with CLP. As shown
in Fig. 7B, hemin and CORM-2 also provided protection
against CLP-induced mice mortality, whereas coadministra-
tion of hemin with ZnPPIX (HO-1 inhibitor) failed to protect
animals from death. These experiments suggest that HO-1
up-regulation and CO protect mice from lethal endotoxemia
and sepsis. Furthermore, no protection was observed against
lethal endotoxemia or CLP-induced sepsis when adminis-
tered RuCl3, a negative control for CORM-2 (Fig. 7, A and B).
Fig. 8. Hemin and CORM-2 pretreat-
ments inhibit HMGB1, TNF-, and IL-1
release during sepsis. A and B, DMSO,
hemin (10 mg/kg), hemin  ZnPPIX (10
and 5 mg/kg i.p., respectively, n  20),
CORM-2 (30 mg/kg), and ruthenium chlo-
ride (30 mg/kg i.p., n  20) were admin-
istrated 2 h before and 12 h after LPS
stimulation (15 mg/kg) (A) or CLP (B).
Plasma was collected by cardiac puncture
24 h after LPS or CLP induction, the
HMGB1 levels were determined by West-
ern blot, and cytokine levels were deter-
mined by ELISA. Thoracic aorta and in-
testine were homogenized and subjected
to Western blot for HO-1 detection. Data
are presented as the mean  S.D. of three
independent experiments. One-way anal-
ysis of variance was used to compare mul-
tiple group means followed by Newman-
Keuls test (significance compared with
control or sham, , P  0.05; significance
compared with LPS or CLP, †, P  0.05).
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Several studies persuade that HMGB1 is a necessary and
sufficient late mediator of the lethal multiple organ failure
associated with severe sepsis (Wang et al., 1999; Yang et al.,
2004). Therefore, we next investigated whether the adminis-
tration of CORM-2 and hemin can attenuate circulating
HMGB1 levels during sepsis. HMGB1 serum level starts to
increase from 24 to 72 h after the initiation of sepsis (Degryse
et al., 2001). To confirm that the reduced serum levels of
HMGB1 by hemin in CLP-sepsis mice are related with HO-1
protein induction (HO-1 activity), we measured the levels of
HO-1 protein expression in the organs (e.g., intestine and
thoracic aorta) of CLP-sepsis mice. As shown in Fig. 8, A and
B, hemin significantly increased HO-1 protein expression in
those organs, which was reduced by ZnPPIX. To match with
this, the increased serum levels of HMGB1 by CLP were
significantly reduced by hemin, which was reversed by Zn-
PPIX (Fig. 8A). Likewise, the administration of CORM-2 but
not RuCl3 significantly reduced the serum levels of HMGB1
in CLP-induced sepsis animals (Fig. 8B).
Hemin and CORM-2 Down-Regulate TNF- and
IL-1 Levels in Septic Mice. We also observed a significant
reduction of serum levels of TNF- and IL-1 in hemin- or
CORM-2-treated mice 24 h after CLP stimulation (Fig. 8, C
and D), and similar results were obtained in LPS-treated
animals (data not shown). Taken together, these results in-
dicate that induction of HO-1 and CO rescue mice from septic
death probably through down-regulation of HMGB1 release.
Delayed Hemin and CORM-2 Administrations Down-
Regulate HMGB1 Levels without Affecting TNF- and
IL-1 and Protect Animal from Death by Lethal LPS-
and CLP-Induced Sepsis. In Fig. 8, we showed that HO-1
inducers and CORM-2 negatively regulate inflammatory cy-
tokines and subsequently improved survival during sepsis.
But it remains unclear whether improved survival is due to
the inhibition of HMGB1 or TNF- and IL-1 together. Keep-
ing in mind that TNF- and IL-1 are induced within hours,
whereas HMGB1 starts to be detected at 16 to 24 h after the
induction of sepsis (data not shown), we treated mice with
hemin or CORM-2 approximately 12 h after the initiation of
endotoxemia by LPS- or CLP-induced sepsis. HMGB1 levels
were significantly decreased in hemin- and CORM-2-treated
groups without significant inhibitory effect on TNF- and
IL-1 and showed significantly improved survival (Figs. 9
and 10). The improved survival was related to HO-1/CO, and
we measured the levels of HO-1 protein expression in the
organs (intestine and thoracic aorta) of CLP-sepsis mice; as
expected, increased expression of HO-1 was shown, although
it was treated 12 h after the initiation of CLP. In contrast,
hemin in combination with ZnPPIX failed to up-regulate
HO-1 and to down-regulate HMGB1 levels. Thus, we can
conclude that inhibitory effect of HO-1/CO on HMGB1 levels
is a necessary action to rescue animals from sepsis.
Discussion
We demonstrated that induction of HO-1 is able to down-
regulate HMGB1 release via CO in activated macrophages.
Up-regulation of HO-1 and CORM-2 also can protect mice
from the lethal effect of LPS- and CLP-induced sepsis model,
and this protection is paralleled by a decrease in the systemic
levels of HMGB1. CORMs are now very useful pharmacolog-
ical tools for the investigation of HO-1-derived CO effect
since Motterlini et al. (2002) first reported. We confirmed the
beneficial effect of HO-1 or CORM-2 against sepsis in mice by
showing the improved survival by treatment with CoPPIX
and hemin during LPS- and CLP-induced sepsis (Foresti et
al., 2005). These facts emphasize the importance of HO-1
against sepsis; however, it needs to be clarified further how
HO-1 induction is beneficial for sepsis. There is growing
evidence that the release of HMGB1 contributes to the pa-
thology and mortality of sepsis, and subsequent inhibition of
HMGB1 protects from sepsis-induced mortality in animals
and humans (Wang et al., 1999, 2004a; Andersson et al.,
2000; Ulloa et al., 2002; Park et al., 2004; Yang et al., 2004;
Sundén-Cullberg et al., 2005). Although HMGB1 was first
implicated as an important endogenous signaling molecule
(Wang et al., 1999) and as a late mediator of endotoxin
related lethality in mice, the relationship between inhibition
of HMGB1 release and HO-1 up-regulation has recently been
reported in LPS-induced acute lung injury (Gong et al.,
2008). The relationship between HO-1 and HMGB1 in an
experimental model of sepsis and septic shock has also been
reported (Takamiya et al., 2008). These authors reported
that circulating levels of HMGB1 were higher in HO-1(/)
mice when treated with a low dose of LPS (5 mg/kg), a dose in
which wild-type mice do not exhibit increased circulating
Fig. 9. Delayed hemin and CORM-2 administration protect against es-
tablished endotoxemia and sepsis. BALB/c mice were subjected to lethal
endotoxemia (LPS, 15 mg/kg i.p.) or sepsis (CLP) and 12 h later were
treated with hemin (10 mg/kg i.p.), hemin  ZnPPIX (10 and 5 mg/kg i.p.,
respectively, n  20), CORM-2 (30 mg/kg i.p.), ruthenium chloride (30
mg/kg i.p., n  20), or DMSO. Treatment was repeated at 24, 48, 72, and
96 h after induction of endotoxemia or sepsis. Survival was monitored
daily for up to 2 weeks. The results are the mean  S.D. of three
independent experiments. , P  0.01 compared with DMSO-treated
animals.
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levels of HMGB1, indicating that a release of HMGB1 from
inflammatory cells is very vulnerable in HO-1-null mice. But
how is HO-1 is responsible for the inhibition of HMGB1
release? To resolve this question, we tested each component
of HO-1 metabolites. First, we used DFO, an iron chelator, to
determine whether the iron ion is responsible for the reduc-
tion of HMGB1 release. If the iron ion is responsible for the
inhibition of HMGB1 release, DFO treatment should block or
at least reverse the action of HO-1 inducers on HMGB1
release. However, DFO does not affect HMGB1 release by
HO-1 inducers in the present study. Hence, we can eliminate
the possibility of involvement of the iron ion in the inhibition
of HMGB1 release by HO-1. Second, we examined whether
bilirubin reduces HMGB1 release in cells activated with LPS,
because bilirubin, another product of HO-1, is documented as
a potent antioxidant in many inflammatory disorders (Ryter
et al., 2006). In particular, bilirubin reduced iNOS and
TNF- and protected animals from hepatotoxicity during
endotoxemia (Wang et al., 2004b). Despite its valuable prop-
erties, bilirubin failed to inhibit LPS-induced HMGB1 re-
lease in our study. Finally, we examined CO. To do so, we
used CORM-2. CORMs already have shown their anti-in-
flammatory properties in many pathological and experimen-
tal models, including septic ones (Bani-Hani et al., 2006;
Cepinskas et al., 2008; Masini et al., 2008). It has been
demonstrated that CO mediates improved survival in septic
animal models by its inhibitory effect on proinflammatory
cytokine production (Bani-Hani et al., 2006; Cepinskas et al.,
2008; Masini et al., 2008). However, inhibition of inflamma-
tory cytokines by neutralizing antibodies or receptor antag-
onists did not show improved survival in animal septic mod-
els and clinical trials (Riedemann et al., 2003). Therefore, it
does not seem convincing that CO improves survival during
sepsis by the inhibition of only inflammatory cytokines. Re-
cently, it was reported that systemic administration of
CORM-2 attenuated inflammation or adhesion molecules ex-
pression by inhibition of activation of nuclear factor-B in
CLP-induced liver of sepsis mice and LPS-treated human
umbilical vein endothelial cells, which underscores again the
importance of anti-inflammatory action of CO (Cepinskas et
al., 2008). However, several reports suggested that HMGB1
inhibition is enough and sufficient to save animals from
death initiated by sepsis or endotoxemia (Wang et al., 1999;
Yang et al., 2004). We found, for the first time, that CO
liberated by CORM-2 can attenuate HMGB1 release in LPS-
treated RAW 264.7 cells. Although it has been reported that
CORMs significantly suppressed the inflammatory response
elicited by LPS in cultured macrophages (Sawle et al., 2005),
there was no report about the effect of CORMs on HMGB1
release. We also demonstrated that administration of HO-1
inducers (hemin, CoPPIX) or CORM-2 significantly reduced
circulating HMGB1 and protected animals from not only
LPS-induced endotoxemia but also CLP-induced sepsis.
Moreover, delayed administration of CORM-2 (12 h after
LPS or CLP) significantly inhibited HMGB1 levels without
alterations in serum levels of TNF- or IL-1, suggesting
that inhibition of HMGB1 is a clue for HO-1 and/or CO-
mediated improved survival. Consistent with a recent report
that CORM-2 was able to suppress the increased circulating
HMGB1 in HO-1(/) mice and rescued HO-1(/) mice
from the lethality of endotoxemia (Takamiya et al., 2008), the
finding of reduced serum levels of HMGB1 by CO and/or
HO-1 inducers implies that CO is important regulator of
HMGB1 release. However, they (Takamiya et al., 2008)
Fig. 10. Delayed hemin and CORM-2 administra-
tion reduce HMGB1 but not TNF- or IL-1 levels in
septic mice. Hemin (10 mg/kg i.p.), CORM-2 (30
mg/kg i.p.), or ruthenium chloride (30 mg/kg i.p., n 
20) were administrated 12 h after CLP or LPS in-
duction. Plasma was collected 24 h after initiation of
sepsis by heart puncture and subjected to HMGB1
analysis or ELISA. Thoracic aorta and intestine
were homogenized and subjected to Western blot for
HO-1 detection. Data are presented as mean  S.D.
of three independent experiments. Significance com-
pared with control or sham, , P  0.05; significance
compared with LPS or CLP, †, P  0.05.
180 Tsoyi et al.
found that biliverdin, another byproduct of HO-1, also signif-
icantly reduced the circulating HMGB1 and rescued
HO-1(/) mice from the mortality of endotoxemia. In the
present study, bilirubin did not reduce HMGB1 release in
LPS-treated RAW 264.7 cells. Based on this result of in vitro
study, we did not further investigate the effect of bilirubin in
in vivo study. As to whether bilirubin reduces circulating
HMGB1 in LPS- or CLP-induced sepsis animals remains to
be elucidated. Although anti-inflammatory effect of CO is
important for attenuation of sepsis-related events (Bani-
Hani et al., 2006), reduction of HMGB1 release is also critical
for the alleviation of septic symptoms and increase of sur-
vival as shown in the present study. Thus, CO, whether it
comes from either HO-1 induction or CO-releasing molecules,
may have a great potential for treatment of sepsis. We found
that ascorbic acid, known to improve the survival of mice
with sepsis, also reduced HMGB1 in LPS-treated RAW 264.7
cells due to CO through the induction of HO-1 (Y. M. Ha,
unpublished observations). It is interesting to note that po-
tent HO-1-inducing agents, such as ()-epigallocatechin-3-
gallate and tanshinone IIA, were identified as potent inhib-
itors of endotoxin-induced HMGB1 release and protected
mice from death by lethal sepsis (Wu et al., 2006; Chen et al.,
2007; Li et al., 2007a,b). Although the molecular mechanism
by which CO prevents release of HMGB1 in activated mac-
rophages and septic animal model has to be elucidated, it can
be speculated that early proinflammatory cytokine produc-
tion such as TNF- can be inhibited by CO, which can, in
turn, affect later the translocation of HMGB1. In fact, proin-
flammatory cytokines produced by endotoxin-stimulated
macrophages/monocytes can be roughly subdivided into two
parts, early- (e.g., TNF and IL-1) and late-phase cytokines
(e.g., HMGB1). However, reciprocal regulation of early- and
late-phase cytokines has been documented (Jiang and Pi-
setsky, 2006). In agreement with previous studies, we dem-
onstrated relationships between TNF-, IL-1, INF-, NO,
and HMGB1 release. Moreover, HO-1 inducers and CORM-2
blocked the expression of early-phase cytokines and NO
(iNOS) production, suggesting that the inhibition of HMGB1
release can go through the inhibition of TNF-, IL-1, INF-,
and NO in LPS-stimulated macrophages. Most important,
however, was the observation that delayed administration of
CORM-2 still inhibited CLP- or LPS-induced HMGB1 release
and improved survival without attenuation of early-phase
cytokine (TNF- or IL-1) levels. This may clearly reflect
that the plasma level of TNF- and IL-1 is already de-
creased to the minimal level at the time of CORM-2 admin-
istration (12 h after LPS or CLP challenge), so no changes
have been observed. Alternately, it may underscore that the
plasma level of HMGB1 is critical for the survival of endo-
toxemia or sepsis. Although it is difficult to explain how CO
inhibits the release HMGB1 at the present time, CO can
inhibit nuclear factor-B activity or p38 mitogen-activated
protein kinase (Ulloa et al., 2002; Bonaldi et al., 2003; Aneja
et al., 2008) or activate peroxisome proliferator-activated
receptor- (Hoetzel et al., 2008). Therefore, further study is
needed to determine whether possible mechanism(s) of CO
exerts on the HMGB1 release by LPS- or CLP-induced sepsis.
Finally, we found that inhibition of COX-2 by NS-398, a
selective COX-2 inhibitor, did not affect HMGB1 release. It
probably explains why specific COX-2 inhibition did not im-
prove survival during lethal sepsis or endotoxemia in mice
(Reddy et al., 2001).
In conclusion, here we report that CO can significantly
attenuate HMGB1 release during sepsis, and this inhibition
is a necessary step of CO in protection against sepsis. In this
way, CO-releasing molecules can be targeted for the devel-
opment of therapeutic agents against systemic inflammatory
disorders, such as sepsis.
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